WUHAN YZY BIOPHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.45 HKD | 0.00% |
|
0.00% | -16.29% |
| Sales 2022 | 2.28M 314K 2.45M | Sales 2023 | 11.97M 1.65M 12.9M | Capitalization | 1.57B 216M 1.69B |
|---|---|---|---|---|---|
| Net income 2022 | -189M -26.09M -204M | Net income 2023 | -192M -26.5M -207M | EV / Sales 2022 * | - |
| Net cash position 2022 | 91.85M 12.68M 99.03M | Net cash position 2023 | 107M 14.71M 115M | EV / Sales 2023 | 122 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-7.81
x | Employees | 123 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.72% |
More Fundamentals
* Assessed data
More news
| 3 months | -13.17% | ||
| 6 months | -11.52% | ||
| Current year | -16.29% |
1 week
7.45
7.45
1 month
7.457.45
Current year
7.458.96
1 year
7.4519.80
3 years
7.4519.80
5 years
7.4519.80
10 years
7.4519.80
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 7.45 | 0.00% | 0 |
| 24-06-05 | 7.45 | 0.00% | 0 |
| 24-06-04 | 7.45 | 0.00% | 0 |
| 24-06-03 | 7.45 | 0.00% | 1,200 |
| 24-05-31 | 7.45 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., June 06, 2024 at 04:08 am EDT
More quotes
Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.29% | 185M | |
| +18.72% | 125B | |
| +14.53% | 109B | |
| -2.88% | 24.74B | |
| +4.51% | 22.67B | |
| -9.54% | 18.14B | |
| -41.04% | 16.67B | |
| -11.83% | 16.64B | |
| +1.46% | 13.45B | |
| +24.22% | 11.32B |
- Stock Market
- Equities
- 2496 Stock
